BZA reduces high-risk biomarkers and provides clinical benefit for hormone receptor (HR)+/HER2- breast cancer patients when combined with CDK4/6 inhibitor palbociclib (NCT02729701, NCT02448771) [66,67]. This evidence concerns the gene CDK4 and breast carcinoma.